{"pmid":32344292,"title":"COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.","text":["COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors.","Eur J Cancer","Leonetti, Alessandro","Facchinetti, Francesco","Zielli, Teresa","Brianti, Elena","Tiseo, Marcello","32344292"],"journal":"Eur J Cancer","authors":["Leonetti, Alessandro","Facchinetti, Francesco","Zielli, Teresa","Brianti, Elena","Tiseo, Marcello"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344292","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.ejca.2020.04.004","topics":["Case Report"],"weight":1,"_version_":1665351883974246400,"score":8.574329,"similar":[{"pmid":32314799,"title":"Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","text":["Letter to the Editor: Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.","Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R","32314799"],"abstract":["Tocilizumab is an interleukin-6 (IL-6) receptor antibody and is progressing as a viable and promising treatment option in patients with severe coronavirus disease 2019 (COVID-19). IL-6 is known to have both immunomodulatory and metabolic actions. In this letter we outline two cases of acute hypertriglyceridemia in patients with COVID-19 treated with tocilizumab: one with elevated biomarkers consistent with acute pancreatitis the other without. Given the paucity of robust clinical trial data for most COVID-19 pharmacotherapies at this time, clinicians should continue to remain steadfast in recognition of interventions that improve clinical outcomes and vigilant in monitoring for acute adverse effects that are difficult to detect in clinical trials with small sample sizes. The observations from our two cases highlight the complex, not fully elucidated interrelationship between elevated IL-6 and pharmacologic interventions impacting this pathway. Clinicians should consider monitoring for hypertriglyceridemia and acute pancreatitis as described with chronic tocilizumab use for rheumatoid arthritis in those receiving it for COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Morrison, Austin R","Johnson, Joseph M","Ramesh, Mayur","Bradley, Patrick","Jennings, Jeffery","Smith, Zachary R"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314799","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25907","keywords":["coronavirus","disease control","immune responses","immunodulators","interleukin","virus classification"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664714520108466176,"score":75.54639},{"pmid":32331519,"title":"Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","text":["Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin.","BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care.","Ann Clin Microbiol Antimicrob","Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J","32331519"],"abstract":["BACKGROUND: COVID-19 pandemics is a challenge for public health and infectious diseases clinicians, especially for the therapeutical approach that is not yet adequately defined. Amid this situation, investigational agents are being used, including chloroquine. We report here the clinical features and therapeutic course of the first reported patient with confirmed COVID-19 pneumonia that recovered in Colombia, after the use of chloroquine and clarithromycin. CASE PRESENTATION: A 34-year-old male, returning from Spain, presented with complaints of fever, and cough, and class-II obesity, being hospitalized. The respiratory viruses and bacteria tested by FilmArray((R)) PCR were negative. Two days later, clarithromycin was started because the patient was suspected as community-acquired pneumonia. At the third day, the rRT-PCR confirmed the SARS-CoV-2 infection. A day later, chloroquine was started because of that. His chest computed tomography was performed and showed bilateral multifocal ground-glass opacities with consolidation, which suggested viral pneumonia as a differential diagnosis. Progressively his clinical condition improved and at day 9, patient rRT-PCR for SARS-CoV-2 became negative. The patient was discharged and isolated at home per 14 days. CONCLUSIONS: Our patient improved significantly. This and other COVID-19 cases are urgently demanding results from clinical trials that support evidence-based therapeutical approaches to this pandemic and the clinical management of patients, especially those at critical care."],"journal":"Ann Clin Microbiol Antimicrob","authors":["Millan-Onate, Jose","Millan, William","Mendoza, Luis Alfonso","Sanchez, Carlos Guillermo","Fernandez-Suarez, Hugo","Bonilla-Aldana, D Katterine","Rodriguez-Morales, Alfonso J"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32331519","week":"202017|Apr 20 - Apr 26","doi":"10.1186/s12941-020-00358-y","keywords":["chloroquine","colombia","coronavirus disease 2019 (covid-19)","latin america","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Colombia","Spain","Colombia"],"countries":["Spain","Colombia"],"countries_codes":["ESP|Spain","COL|Colombia"],"e_drugs":["Clarithromycin","Chloroquine"],"_version_":1665071049689006080,"score":71.38618},{"pmid":32165205,"pmcid":"PMC7126344","title":"Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19.","text":["Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19.","Ann Oncol","Qu, J","Yang, R","Song, L","Kamel, I R","32165205"],"journal":"Ann Oncol","authors":["Qu, J","Yang, R","Song, L","Kamel, I R"],"date":"2020-03-14T11:00:00Z","year":2020,"_id":"32165205","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.annonc.2020.03.001","source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664640874762469376,"score":71.03533},{"pmid":32314010,"title":"Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","text":["Coronavirus Disease 19 (COVID-19) complicated with pneumonia in a patient with rheumatoid arthritis receiving conventional disease-modifying antirheumatic drugs.","In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.","Rheumatol Int","Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho","32314010"],"abstract":["In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications."],"journal":"Rheumatol Int","authors":["Song, Jehun","Kang, Seongmin","Choi, Seung Won","Seo, Kwang Won","Lee, Sunggun","So, Min Wook","Lim, Doo-Ho"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314010","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s00296-020-04584-7","keywords":["covid-19","coronavirus","disease-modifying antirheumatic drugs","pneumonia","rheumatoid arthritis"],"source":"PubMed","topics":["Case Report"],"weight":1,"locations":["Wuhan","China","myalgia"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["lopinavir-ritonavir drug combination","Hydroxychloroquine"],"_version_":1664714520041357312,"score":62.566616},{"pmid":32114094,"pmcid":"PMC7128866","title":"Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.","text":["Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.","There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia.","J Thorac Oncol","Tian, Sufang","Hu, Weidong","Niu, Li","Liu, Huan","Xu, Haibo","Xiao, Shu-Yuan","32114094"],"abstract":["There is currently a lack of pathologic data on the novel coronavirus (severe acute respiratory syndrome coronavirus 2) pneumonia, or coronavirus disease 2019 (COVID-19), from autopsy or biopsy. Two patients who recently underwent lung lobectomies for adenocarcinoma were retrospectively found to have had COVID-19 at the time of the operation. These two cases thus provide important first opportunities to study the pathology of COVID-19. Pathologic examinations revealed that apart from the tumors, the lungs of both patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells. Hyaline membranes were not prominent. Because both patients did not exhibit symptoms of pneumonia at the time of operation, these changes likely represent an early phase of the lung pathology of COVID-19 pneumonia."],"journal":"J Thorac Oncol","authors":["Tian, Sufang","Hu, Weidong","Niu, Li","Liu, Huan","Xu, Haibo","Xiao, Shu-Yuan"],"date":"2020-03-02T11:00:00Z","year":2020,"_id":"32114094","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.jtho.2020.02.010","keywords":["covid-19 pneumonia","coronavirus","pathology","sars-cov-2"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1664640875063410689,"score":61.33767}]}